Formulation and evaluation of Fluconazole Nanosuspensions: In vitro characterization and transcorneal permeability studies.
| Autor: | Aldosari BN; Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11495, Saudi Arabia., Ibrahim MA; Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11495, Saudi Arabia., Alqahtani Y; Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11495, Saudi Arabia., Abou El Ela AESF; Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11495, Saudi Arabia. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society [Saudi Pharm J] 2024 Jul; Vol. 32 (7), pp. 102104. Date of Electronic Publication: 2024 May 16. |
| DOI: | 10.1016/j.jsps.2024.102104 |
| Abstrakt: | The aim in this study was to develop and evaluate a nanofluconazole (FLZ) formulation with increased solubility and permeation rate using nanosuspensions. The FLZ nanosuspensions were stabilized using a variety of stabilizing agents and surfactants in various concentrations. The FLZ nanosuspension was characterized in vitro using particle size, zeta potential, X-ray powder diffraction (XRPD), and solubility. In addition, the ex vivo ocular permeation of FLZ through a goat cornea was analyzed. The results showed that the particle size of all nanosuspension formulations was in the nanometer range from 174.5 ± 1.9 to 720.2 ± 4.77 nm; that of the untreated drug was 18.34 μm. The zeta potential values were acceptable, which indicated suitable stability for formulations. The solubility of the nanosuspensions was up to 5.7-fold higher compared with that of the untreated drug. The results of the ex vivo ocular diffusion of the FLZ nanosuspensions showed the percentage of FLZ penetrating via the goat cornea increased after using Kollicoat to stabilize the nanosuspension formulation. Consequently, when using a nanosuspension formulation of Kollicoat, the antifungal activity of the drug strengthens. Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (© 2024 The Authors.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|